CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
For the period ended Jun 27, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 27, 2026 · Filed Aug 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides information relating to the purchases of shares of our common stock during the three months ended June 27, 2026.
| Total Numberof SharesPurchased · AveragePrice Paidper Share · Total Number ofShares Purchasedas Part of PubliclyAnnounced Plansor Programs · Approximate DollarValue of SharesThat May Yet BePurchased Underthe Plans or Programs | |||||
|---|---|---|---|---|---|
| (in thousands) | |||||
| March 29, 2026 to April 25, 2026 | — | $— | — | $800,000 | |
| April 26, 2026 to May 23, 2026 | — | — | — | 800,000 | |
| May 24, 2026 to June 27, 2026 | 647,660 | 173.57 | 576,059 | 700,000 | |
| Total | 647,660 | 576,059 | |||
On October 29, 2025, our Board of Directors approved, in aggregate, a stock repurchase program of $1.0 billion. During the three months ended June 27, 2026, we repurchased 0.6 million shares of common stock for $100.0 million under the stock repurchase program. As of June 27, 2026, we had $700.0 million remaining on the authorized $1.0 billion stock repurchase program.
Additionally, our stock-based compensation plans permit the netting of common stock upon vesting of restricted stock units, and performance share units in order to satisfy individual statutory tax withholding requirements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.